Inhaled nintedanib for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have been diagnosed with IPF according to current guidelines.
- You either haven't taken any IPF treatment before, or you've been on a steady dose of pirfenidone or nerandomilast for at least 3 months.
- You weigh more than 88 pounds (40 kg).
- If you can become pregnant, you agree to use approved birth control and have negative pregnancy tests. If you can father a child, you agree to use approved birth control and not donate sperm during the study and for a few months after.
- You are willing to follow the study rules, attend visits, and complete lung function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a cough suppressant called dextromethorphan to the standard IPF medication nintedanib helps improve cough and lung function better than nintedanib alone. It is a 12-week treatment phase with a 1-week follow-up, designed for people with moderate IPF.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.